Cargando…

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy

Human epidermal growth factor receptor 2 (HER2) is overexpressed in around 20–30% of breast cancer tumors. It is associated with a more aggressive disease, higher recurrence rate, and increased mortality. Trastuzumab is a HER2 receptor blocker that has become the standard of care for the treatment o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mitri, Zahi, Constantine, Tina, O'Regan, Ruth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539433/ https://www.ncbi.nlm.nih.gov/pubmed/23320171 http://dx.doi.org/10.1155/2012/743193

Ejemplares similares

New and emerging treatments for estrogen receptor-positive breast cancer: focus on everolimus
por: Paplomata, Elisavet, et al.
Publicado: (2013)

AR Signaling in Breast Cancer
por: Rahim, Bilal, et al.
Publicado: (2017)

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells
por: Ozbay, Tuba, et al.
Publicado: (2009)

PI3Kinase Inhibition in Hormone Receptor-Positive Breast Cancer
por: Dhakal, Ajay, et al.
Publicado: (2021)

Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab
por: Al Rabadi, Luai S., et al.
Publicado: (2021)

New Advances in Targeted Therapy of HER2-Negative Breast Cancer
por: An, Junsha, et al.
Publicado: (2022)

A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
por: Hurvitz, Sara A., et al.
Publicado: (2013)

Neoadjuvant Hormonal Therapy is Associated with Comparable Outcomes to Neoadjuvant Chemotherapy in Post-Menopausal Women with Estrogen Receptor-Positive Breast Cancer
por: Marcus, David M., et al.
Publicado: (2013)

Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer
por: Taylor, Caitlin, et al.
Publicado: (2023)

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: West, Malinda T, et al.
Publicado: (2023)

HER2 status and breast cancer therapy: recent advances
por: Tripathy, Debu
Publicado: (2009)

Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR(+)/HER2(−) Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial
por: Lu, Yen-Shen, et al.
Publicado: (2022)

53. TUCATINIB VS PLACEBO ADDED TO TRASTUZUMAB AND CAPECITABINE FOR PATIENTS WITH PREVIOUSLY TREATED HER2+ METASTATIC BREAST CANCER (MBC) WITH BRAIN METASTASES (BM) (HER2CLIMB)
por: Lin, Nancy, et al.
Publicado: (2020)

Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer
por: Miles, David W
Publicado: (2009)

Modulation of the BRCA1 Protein and Induction of Apoptosis in Triple Negative Breast Cancer Cell Lines by the Polyphenolic Compound Curcumin
por: Rowe, Danica L., et al.
Publicado: (2009)

HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks
por: Mandó, Pablo, et al.
Publicado: (2023)

Advances in e-learning in undergraduate clinical medicine: a systematic review
por: Delungahawatta, T., et al.
Publicado: (2022)

New Agents for the Management of Advanced HER2-Positive Breast Cancer
por: Royce, Melanie, et al.
Publicado: (2016)

Osteopetrosis, Hypophosphatemia, and Phosphaturia in a Young Man: A Case Presentation and Differential Diagnosis
por: Mitri, Zahi, et al.
Publicado: (2012)

Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
por: Morrow, Phuong Khanh H, et al.
Publicado: (2009)

The Long-HER Study: Clinical and Molecular Analysis of Patients with HER2+ Advanced Breast Cancer Who Become Long-Term Survivors with Trastuzumab-Based Therapy
por: Gámez-Pozo, Angelo, et al.
Publicado: (2014)

Ovarian Cancer: Advances in Pathophysiology and Therapies
por: Tossetta, Giovanni, et al.
Publicado: (2023)

Pathophysiology and new advances in pulmonary hypertension
por: Bousseau, Simon, et al.
Publicado: (2023)

microRNAs Orchestrate Pathophysiology of Breast Cancer Brain Metastasis: Advances in Therapy
por: Kanchan, Ranjana K., et al.
Publicado: (2020)

New Therapeutics in HER2-Positive Advanced Breast Cancer: Towards a Change in Clinical Practices?
por: Mezni, Essia, et al.
Publicado: (2020)

New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
por: MacNeil, Ian A., et al.
Publicado: (2020)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups
por: Umemneku-Chikere, Chinyereugo M., et al.
Publicado: (2022)

P34 Impact of medical microbiology lead antimicrobial stewardship rounds on antimicrobial consumption in a level 3 hospital
por: Lucey, Mary, et al.
Publicado: (2022)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
por: Ditsch, Nina, et al.
Publicado: (2019)

Frequent Upregulation Of HER2 Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After Short-Term Neoadjuvant Endocrine Therapy
por: Chaudhary, Lubna Naaz, et al.
Publicado: (2023)

Effect of HER2 expression status on the prognosis of patients with HR(+)/HER2(‑) advanced breast cancer undergoing advanced first‑line endocrine therapy
por: Wang, Kan, et al.
Publicado: (2023)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
por: Musolino, Antonino, et al.
Publicado: (2022)

Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer
por: Mu, Yuxin, et al.
Publicado: (2023)

A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2- advanced breast cancer patients with HER2 mutations
por: Ma, Jing, et al.
Publicado: (2022)

HER2 Aberrations in Non-Small Cell Lung Cancer: From Pathophysiology to Targeted Therapy
por: Vathiotis, Ioannis A., et al.
Publicado: (2021)

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
por: Lin, Nancy U., et al.
Publicado: (2020)

Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
por: Stanowicka-Grada, Malwina, et al.
Publicado: (2023)

Advances in HER2-Positive Breast Cancer: Novel Therapies and Adverse Event Management
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_3l06u4r5rmj0nrdpk7204vi7rf